We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies.

X

The West Blog

Latest Post

July 31, 2017

Growth in GLP-1 Drugs May Offer Improved Outcomes to People with Type II Diabetes

The rise in type 2 diabetes has sparked a variety of treatment options, including glucagon-like peptide-1 (GLP-1) receptor agonists. GLP-1s are a class of injected drugs (additional oral options are currently in development) that &ldquo;mimic the action of GLP-1 and increase the incretin effect in patients with type 2 diabetes, stimulating the release of insulin.&rdquo;<sup>1</sup> Commonly used when oral treatment alone is not enough, the benefits of GLP-1s include a reduction of glucagon and glycosylated haemoglobin (HbA1c), weight loss and a low risk of hypoglycemia.<sup>2</sup>
Aileen Kinsella

Aileen Kinsella

Director, Segment Marketing, Pharma

Subscribe to receive the latest blog post

Categories

Search the Blog

Archive

{1}

{2}
{3}

{4}

  • Previous Posts
    Diabetes Blog Card

    April 04, 2017

    New Solutions for Diabetes Glucose Monitoring Aid Patient Success

    Aileen Kinsella

    Aileen Kinsella

    Director, Segment Marketing

    World Diabetes Day

    November 14, 2016

    Eyes on World Diabetes Day

    West Pharma

    Heino Lennartz

    Vice President & General Manager, Global Pharma